TB-500 and PPIs (Omeprazole, Pantoprazole) Interaction: What the Evidence Actually Shows

What Is TB-500 and How Is It Cleared?

TB-500 is the synthetic active fragment of thymosin beta-4 (Tβ4), a 43-amino-acid actin-sequestering protein expressed in virtually every human tissue. The peptide promotes actin polymerization, reduces local inflammatory signaling, and may support wound healing and angiogenesis in preclinical models. Researchers have studied full-length Tβ4 in cardiac repair, corneal wound healing, and skin regeneration.

Route of Administration and Bioavailability

Clinically, TB-500 is dispensed as a lyophilized powder reconstituted for subcutaneous or intramuscular injection. This route bypasses first-pass hepatic metabolism entirely. Oral bioavailability of peptides in the 2 kDa range is typically below 2% without specialized delivery technology, so peptide drugs of this molecular weight class are almost universally injected.

Because TB-500 never transits the gastrointestinal lumen after subcutaneous injection, any drug that alters gastric acid, gastric motility, or intestinal absorption simply has no target to act on. Omeprazole's primary mechanism, irreversible inhibition of the H+/K+-ATPase proton pump, is therefore pharmacologically irrelevant to TB-500 systemic exposure.

Proteolytic Clearance: Why CYP450 Is Not the Issue

Small-molecule drugs are typically metabolized by hepatic CYP isoforms. Peptides are not. TB-500 is broken down by endopeptidases and exopeptidases in plasma and tissues into individual amino acids. Peptide half-life is governed by protease activity, renal filtration of fragments, and molecular weight, not by CYP2C19, CYP3A4, or CYP2D6.

Omeprazole and pantoprazole, by contrast, are almost entirely eliminated via CYP2C19 (primary) and CYP3A4 (secondary). The FDA-approved labeling for omeprazole specifically identifies CYP2C19 as the dominant metabolic pathway. That pathway is simply not shared with a subcutaneous peptide.

How PPIs Work and Where Interactions Typically Arise

Proton pump inhibitors are among the most prescribed drug classes worldwide. A 2022 analysis estimated that approximately 8% of U.S. Adults used a PPI in the prior 30 days. Understanding where they cause interactions clarifies why TB-500 sits outside that risk zone.

CYP2C19 Inhibition: The Classic PPI Interaction Mechanism

Omeprazole is both a CYP2C19 substrate and a moderate CYP2C19 inhibitor. Pantoprazole causes less CYP2C19 inhibition than omeprazole at standard doses. The FDA label for omeprazole warns about reduced clopidogrel efficacy because omeprazole inhibits CYP2C19-mediated conversion of clopidogrel to its active metabolite. This is the canonical PPI drug interaction, and it applies only to drugs that require CYP2C19 for activation or elimination.

TB-500 requires neither.

pH-Dependent Absorption: Relevant for Oral Drugs, Not Injected Peptides

Several oral drugs rely on an acidic gastric environment for solubilization and absorption. PPIs raise intragastric pH to above 4.0 for the majority of a 24-hour period, which can reduce absorption of ketoconazole, erlotinib, atazanavir, and other pH-sensitive drugs by 30 to 90%. The Lexicomp DDI database documents over 200 clinically significant pH-dependent absorption interactions with PPIs.

None of this applies to subcutaneously injected TB-500. The drug never encounters the gastric environment.

P-Glycoprotein: A Minor Consideration

Pantoprazole and omeprazole have minor P-glycoprotein inhibitory activity at supratherapeutic concentrations in vitro. In vivo Pgp interactions with standard PPI doses are not considered clinically significant by FDA interaction guidance. TB-500 is not a known Pgp substrate, so this theoretical mechanism does not produce a clinically actionable interaction.

TB-500's Pharmacodynamic Profile and Overlap with PPI Effects

Even when two drugs share no pharmacokinetic interaction, they can still produce additive, synergistic, or antagonistic pharmacodynamic effects. Reviewing the known biology of Tβ4 alongside PPI pharmacodynamics reveals one area of potential overlap and no areas of antagonism.

Gastric Mucosal Protection: Additive, Not Harmful

Thymosin beta-4 has demonstrated gastroprotective properties in preclinical studies. A 2010 study in rats published in the American Journal of Physiology found that Tβ4 reduced ethanol-induced gastric ulceration by suppressing NF-κB activation and promoting mucosal cell migration. PPIs reduce acid-mediated mucosal injury. These two mechanisms are complementary. Co-administration is more likely to produce additive mucosal protection than any adverse interaction.

No animal model or human report documents antagonism between Tβ4 and acid-suppression therapy.

Anti-Inflammatory Overlap

Thymosin beta-4 downregulates NF-κB-driven cytokine production, including TNF-alpha and IL-1beta, in injured tissue. A 2016 review in Expert Opinion on Biological Therapy summarized evidence that Tβ4 modulates inflammatory pathways relevant to fibrosis, ischemia, and wound healing. PPIs also carry modest anti-inflammatory properties in esophageal epithelium, primarily through NOX activity reduction. These effects operate on different tissue beds and different signaling nodes; no pharmacodynamic antagonism has been reported.

Wound Healing and Collagen Synthesis

One reason patients use TB-500 off-label is to accelerate soft-tissue repair. PPIs do not inhibit collagen synthesis, angiogenesis, or actin polymerization. The two drugs operate on entirely separate biological targets. Combining them introduces no known mechanism by which PPI use could blunt TB-500's intended tissue-repair effects.

Regulatory Status and Compounding Context

This interaction question cannot be fully addressed without noting the regulatory status of TB-500. Full-length thymosin beta-4 (the peptide from which TB-500 is derived) is not FDA-approved for any indication. The FDA placed thymosin beta-4 on its list of bulk drug substances that may not be used in compounding under section 503A. TB-500, as a truncated active fragment, occupies a regulatory gray area that varies by state pharmacy board and individual 503A compounding pharmacies.

Patients obtaining TB-500 from compounding pharmacies receive no FDA-reviewed prescribing information, no standardized dosing insert, and no formal DDI assessment from the agency. That absence of data is not evidence of safety; it reflects an evidence gap that clinicians must acknowledge explicitly when counseling patients.

By contrast, both omeprazole and pantoprazole carry full FDA labeling with documented interaction profiles. Omeprazole 20 mg and 40 mg oral capsules and pantoprazole 40 mg oral tablets are reviewed under NDA 019810 and NDA 020987, respectively. The pantoprazole FDA label documents its CYP2C19/CYP3A4 metabolism and identifies methotrexate as a drug requiring caution due to PPI-related transporter inhibition.

What the DDI Databases Actually Show

Clinicians routinely check interaction databases such as Lexicomp, Micromedex, and Clinical Pharmacology before prescribing. Thymosin beta-4 and its active fragments, including TB-500, are not indexed in any of these databases as of mid-2025. The absence of an indexed interaction reflects the absence of formal pharmacokinetic study, not a confirmed clean interaction profile.

Reading the Absence of Data Correctly

When a drug is not in the DDI database, clinicians apply first-principles pharmacology. The relevant questions are:

• Does Drug A share metabolic enzymes with Drug B? For TB-500 and PPIs: No.
• Does Drug A rely on gastrointestinal absorption that could be altered by Drug B? For TB-500 and PPIs: No.
• Does Drug A or Drug B alter plasma protein binding significantly? PPIs are highly protein-bound (>95%), but TB-500 peptide fragments are not competing for the same binding sites on albumin.
• Is there a pharmacodynamic mechanism for antagonism? For TB-500 and PPIs: No identified mechanism.

This first-principles analysis consistently arrives at the same conclusion: the interaction risk is low.

Severity Classification

Standard DDI severity systems (Lexicomp A/B/C/D/X scale; Micromedex contraindicated/major/moderate/minor scale) would classify this combination as a Category A or "no known interaction" if the peptide were indexed. The pharmacological rationale for any classification above minor is absent.

Clinical Monitoring Parameters

Even with a low interaction risk, patients co-using TB-500 and a PPI deserve a structured monitoring framework. The following parameters are reasonable given what is known about each agent individually.

For the PPI Component

Patients on long-term PPI therapy (defined as more than 8 weeks continuous use) warrant monitoring for:

• Hypomagnesemia: The FDA issued a drug safety communication in 2011 noting that PPIs taken for more than one year may cause symptomatic hypomagnesemia, with serum magnesium below 0.75 mmol/L in reported cases. A baseline and annual magnesium level is appropriate.
• Vitamin B12 status: A case-control study (N=25,956) published in JAMA in 2013 found that PPI use for more than 2 years was associated with a 65% increased risk of vitamin B12 deficiency. Annual B12 screening is reasonable for long-term users.
• Bone density: A 2016 systematic review and meta-analysis in Osteoporosis International (pooled N>300,000) found PPI use associated with a relative risk of 1.26 for hip fracture. DEXA scanning per standard guidelines is appropriate in at-risk patients.

For the TB-500 Component

Because TB-500 carries no FDA label, no formal monitoring schedule exists. Reasonable parameters drawn from the peptide's known biology include:

• Injection site inspection at each clinical visit for signs of induration, granuloma formation, or infection.
• Baseline and periodic CBC and CMP to detect any unexpected hematologic or renal change, given that proteolytic fragment clearance involves renal excretion of small amino acids.
• Blood pressure monitoring, since Tβ4 has been studied in angiogenesis models and theoretical concern about neovascularization exists, though no clinical hypertension signal has been reported in human case series.

Patient Counseling Points

Patients asking whether they can take TB-500 alongside their omeprazole or pantoprazole deserve a direct, evidence-anchored answer, not vague reassurance.

The counseling conversation should cover four specific points.

First, the most pharmacologically relevant fact: because TB-500 is injected rather than swallowed, PPIs cannot alter how much of it reaches the bloodstream. That eliminates the most common PPI interaction mechanism outright.

Second, the regulatory gap: TB-500 has no FDA-approved label, meaning no formal interaction study has been conducted or required. The absence of a documented interaction is not the same as a confirmed safe interaction. Patients should understand this distinction.

Third, the PPI risks are independent of TB-500. Long-term omeprazole or pantoprazole use carries its own risk profile involving magnesium, B12, and bone density regardless of what else the patient is taking. Those risks deserve attention on their own terms.

Fourth, the provider network matters. Patients using compounded peptides and prescription medications simultaneously should have a single clinician, or at least a clearly communicating care team, reviewing all agents together. Fragmented prescribing increases the probability of an undetected problem, even when the known pharmacology appears low-risk.

Special Populations

CYP2C19 Poor Metabolizers

Approximately 2 to 5% of European-ancestry individuals and up to 15 to 20% of East Asian-ancestry individuals carry loss-of-function CYP2C19 alleles. Pharmacogenomic data reviewed in Clinical Pharmacology and Therapeutics confirms that CYP2C19 poor metabolizers show 3 to 10-fold higher omeprazole AUC compared to extensive metabolizers. Higher omeprazole exposure does not change the TB-500 interaction picture, because the interaction mechanism does not involve CYP2C19. It does, however, mean that CYP2C19 poor metabolizers may need lower PPI doses for acid suppression goals, independent of any peptide use.

Renal Impairment

Patients with estimated GFR below 30 mL/min/1.73m2 may retain peptide fragments longer due to reduced renal filtration. No dose adjustment recommendations exist for TB-500 in renal impairment because no formal pharmacokinetic study has been conducted. PPI dosing is generally unchanged in renal impairment. FDA labeling for pantoprazole states no dose adjustment is required in renal impairment.

Older Adults

Adults over 65 years are more likely to be on long-term PPI therapy and more susceptible to hypomagnesemia and fracture risk from that therapy. A 2010 FDA safety communication specifically highlighted fracture risk in patients over 50 on long-term or high-dose PPIs. TB-500 use in this population is not well-characterized; clinicians should be conservative and apply close follow-up.